Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 91 of 95, showing 5 Applications out of 474 total, starting on record 451, ending on 455

# Protocol No Study Title Investigator(s) & Site(s)

451.

ECCT/19/04/01   A study to determine if a new shigella vaccine (Shigella4V) is safe, induces immunity and the best dose among Kenyan infants.
    Safety and immunogenicity of a Shigella-tetravalent bioconjugate vaccine: A phase 1/2 randomized controlled and age descending study including dose finding in 9-month-old infants   
Principal Investigator(s)
1. Mainga Hamaluba
2. Kosgei Josphat
Site(s) in Kenya
1. KEMRI-United States Army Medical Research Unit-Kenya, Kericho (Kericho county)
2. KEMRI Wellcome Trust Research Program-CGMR-C (Kilifi county)
 
View

452.

ECCT/09/09/02   MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN
    SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN   
Principal Investigator(s)
1. LUCAS OTIENO TINA
2. MARY HAMEL
Site(s) in Kenya
1. KEMRI-CDC, (Siaya county)
2. KEMRI-WRP (Kisumu county)
 
View

453.

ECCT/20/06/01   IAVI C100
    Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults   
Principal Investigator(s)
1. Prof Walter Jaoko Godfrey Jaoko
Site(s) in Kenya
1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county)
 
View

454.

ECCT/15/10/01   VRC01 Monoclonal HIV Antibodies Study
    Safety  and  Virologic Effect  Of  A  Human   Monoclonal   Antibody,   VRC-HIVmAb060-00-Ab  (VRCOl),   With Broad  HIV-1  Neutralizing Activity, Administered Intravenously to Adults  During Early Acute HIV Infection.   
Principal Investigator(s)
1. Josphat K Kosgei
Site(s) in Kenya
KEMRI Walter Reed Project Kericho
 
View

455.

ECCT/19/11/01   A study to determine if candidate malaria vaccines are safe, effective, and induce immunity among Kenyan adults.
    Safety, immunogenicity, and efficacy of R21/Matrix M (R21/MM) and ChAd63/MVA-ME-TRAP in the context of controlled human malaria infection: A Phase IIb Trial in Kenyan Adults.   
Principal Investigator(s)
1. Melissa Kapulu
Site(s) in Kenya
KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (CGMRC), Kilifi, Kenya.
 
View